GHK-Cu dosage chart
50 mg Vial
This GHK-Cu dosage chart explains a 50 mg vial prepared to a final volume of 3.0 mL for a concentration of 16.67 mg/mL. The GHK-Cu dosage protocol examples below cover 1.0 mg, 1.5 mg, and 2.0 mg amounts, with matching U-100 syringe units, reconstitution steps, supplies, and research context.
- Reconstitute
- Prepare the 50 mg vial to a final volume of 3.0 mL for a concentration of 16.67 mg/mL.
- Research protocol range
- The tables below cover 1.0 mg, 1.5 mg, and 2.0 mg using the standard and alternative research-use schedules.
- Easy measuring
- At 16.67 mg/mL, 1 U-100 unit = 0.01 mL = approximately 166.7 mcg.
- Quick conversions
- 1.0 mg = 6 units, 1.5 mg = 9 units, and 2.0 mg = 12 units.
Dosing schedule
| Week/Phase | Dose per Injection | Units (per injection) (mL) |
|---|---|---|
| Weeks 1-4 | 1.0 mg (1000 mcg) | 6 units (0.06 mL) |
| Weeks 5-8 | 1.5 mg (1500 mcg) | 9 units (0.09 mL) |
| Weeks 9-12+ | 2.0 mg (2000 mcg) | 12 units (0.12 mL) |
Reconstitution Steps
| Week/Phase | Dose per Injection | Units (per injection) (mL) |
|---|---|---|
| Weeks 1-12+ | 2.0 mg (2000 mcg) | 12 units (0.12 mL) |
Reconstitution steps
- 1Draw 3.0 mL of the protocol-specified sterile diluent with a sterile syringe.
- 2Add it slowly down the vial wall to reduce foaming.
- 3Gently swirl or roll until dissolved. Do not shake.
- 4Label the vial with the 16.67 mg/mL concentration, preparation date, and storage instructions.
Important Notes
Practical considerations for consistent research preparation and recordkeeping.
Published human GHK-Cu research has primarily evaluated topical and wound-care formulations, while local administration in an animal wound model provides additional preclinical context. The subcutaneous schedules above are research-use practice conventions, so findings should be interpreted according to route and formulation. Current clinical-trial and FDA materials provide additional topical, compounding, and regulatory context.
- Use new sterile equipment for each preparation or administration and use a suitable sharps container.
- Follow the written protocol for site selection and rotation.
- Use aseptic technique and allow skin antiseptic to dry before administration.
- Document the amount, date, preparation identifier, and site used.
How This Works
GHK-Cu is a naturally occurring copper-binding tripeptide studied in extracellular-matrix signaling, collagen-related pathways, antioxidant defense, and tissue remodeling. Human studies provide topical and wound-care context, while an animal wound model provides local-administration context.
Potential Benefits & Observed Effects
Findings reported in the GHK-Cu research literature.
- Supports research into collagen-related signaling, extracellular-matrix remodeling, and tissue repair.
- Human topical and wound-care studies have examined skin and tissue outcomes in formulation-specific settings.
- Human-skin penetration research provides additional topical-delivery context.
- Observed findings depend on route, formulation, concentration, and study design; the supporting context is summarized in Important Notes above.
Lifestyle Factors
Complementary approaches to support tissue health and regeneration.
- Maintain adequate protein intake to support collagen synthesis and tissue repair processes.
- Ensure sufficient hydration and micronutrient status (particularly copper, zinc, vitamin C) for optimal connective tissue metabolism.
- Prioritize sleep quality and stress management to support regenerative biological processes.
- Consider combining with appropriate skincare or wound-care protocols as relevant to individual goals.
Injection Technique
General subcutaneous technique references are included for preparation and measurement context.
- Follow aseptic technique and use new sterile equipment for each administration.
- Use the protocol-specified site, angle, and device; the CDC job aid illustrates general subcutaneous technique.
- Rotate sites systematically and document each administration.
- Dispose of used sharps immediately in an appropriate container.
important-note
This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.
GHK-Cu dosage FAQs
How much bacteriostatic water do you use to reconstitute GHK-Cu?
Prepare the 50 mg vial to a final volume of 3.0 mL for a concentration of 16.67 mg/mL. for a 50 mg Vial vial. Add the water slowly against the inside wall of the vial and swirl — never shake — until the powder fully dissolves.
What does the GHK-Cu dosing schedule look like?
Weeks 1-4 — 1.0 mg (1000 mcg) — 6 units (0.06 mL); Weeks 5-8 — 1.5 mg (1500 mcg) — 9 units (0.09 mL); Weeks 9-12+ — 2.0 mg (2000 mcg) — 12 units (0.12 mL). The full table above lists every step with matching syringe units.
What are the mixing steps for GHK-Cu?
Draw 3.0 mL of the protocol-specified sterile diluent with a sterile syringe. Add it slowly down the vial wall to reduce foaming. Gently swirl or roll until dissolved. Do not shake.
How should reconstituted GHK-Cu be stored?
Once mixed, GHK-Cu is kept refrigerated at roughly 2–8 °C, protected from light, and never frozen. Unmixed lyophilised powder is the more stable form and is only reconstituted when it is needed.
How many insulin syringe units equal a GHK-Cu dose?
Units depend on the water volume you used. Divide your target dose by the vial concentration to get millilitres, then multiply by 100 — 1 unit on a U-100 insulin syringe is 0.01 mL. The Spartan Peptides reconstitution calculator does this conversion for you.
Is GHK-Cu approved for human use?
No. GHK-Cu is sold and referenced strictly as a research chemical. Nothing on this page is medical advice and the material is not for human consumption.
Educational and research information only. Not medical advice, not for human consumption. Values are reference figures — always verify your own math with the reconstitution calculator.
On any insulin syringe, 1 unit = 0.01 mL, so unit counts above hold across brands.